Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Analysis of PFS in CLL: Pts Who Received First-Line Bendamustine-Rituximab Depending on The Elimination Rate of The MRD and IGHV

9 views
March 30, 2020
0 Comments
Login to view comments. Click here to Login
Hematologic Oncology